Healthcare Industry News: schizophrenia
News Release - April 2, 2014
EnVivo Pharmaceuticals, Inc. Becomes FORUM Pharmaceuticals Inc.WATERTOWN, Mass.--(Healthcare Sales & Marketing Network)--EnVivo Pharmaceuticals, Inc. announced today that the company has changed its name to FORUM Pharmaceuticals Inc. The new name better reflects the company’s strong position as a late-stage, purpose-built organization that is focused on conquering challenging brain diseases such as schizophrenia and Alzheimer’s disease. It is not associated with any changes in organizational structure or the company’s investor base.
“The name FORUM captures our commitment to perseverance and innovation, and highlights our bold approach to bringing new therapies to help people with serious brain diseases overcome their everyday symptoms,” said Deborah Dunsire, M.D., President and Chief Executive Officer of FORUM. “Historically, a forum is a place where people come together to debate and share ideas. As FORUM Pharmaceuticals, we are combining that spirit of collaboration with a singular focus on brain disease, to find and develop new medicines that improve patients’ abilities to function – striving to help them maintain critical connections, live more fully, and ultimately, to change the course of their disease.”
FORUM has a robust and diverse pipeline focused on innovative solutions for neuropsychiatric conditions. The Company’s lead compound, encenicline hydrochloride (EVP-6124), is a novel alpha-7 (a7) potentiator currently being evaluated in separate ongoing Phase 3 COGNITIV clinical trial programs. The first trial is focused on patients with cognitive impairment in schizophrenia (COGNITIV CIAS). The second is focused on improving cognition in patients with Alzheimer’s disease (COGNITIV AD).
schizophrenia is a psychiatric disorder that affects approximately 2.4 million Americans, or about one percent of the adult population, and is usually diagnosed between the ages of 15 and 35 years old. For more information about cognitive impairment in schizophrenia, please visit www.needrecognition.com.
About FORUM Pharmaceuticals Inc.
FORUM Pharmaceuticals Inc. and its subsidiaries (“FORUM Pharmaceuticals” or “FORUM”) are dedicated to developing groundbreaking medicines in support of all those who are affected by or caring for people with serious brain disease, to help them live fuller, more enriching lives. The Company’s robust and diverse pipeline is focused on discovering and developing new treatments for important neurodegenerative diseases that explore novel mechanisms of action to potentially alter the progression of brain disease and provide improvement in cognitive and overall function. FORUM’s lead compound, encenicline hydrochloride (EVP-6124), is currently being evaluated in separate ongoing Phase 3 clinical trial programs: COGNITIV CIAS, which looks to improve cognitive impairment in patients with schizophrenia, and COGNITIV AD, which aims to improve cognition in patients with Alzheimer’s disease. Privately owned, FORUM Pharmaceuticals is based in Watertown, Mass. For more information about FORUM, visit www.forumpharma.com.
FORUM Pharmaceuticals and the FORUM octagon logo are trademarks of FORUM Pharmaceuticals Inc.
Source: EnVivo Pharmaceuticals
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.